- Home
- Publications
- Publication Search
- Publication Details
Title
Development and strategies of VEGFR-2/KDR inhibitors
Authors
Keywords
-
Journal
Future Medicinal Chemistry
Volume 4, Issue 14, Pages 1839-1852
Publisher
Future Science, LTD
Online
2012-10-09
DOI
10.4155/fmc.12.121
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tivozanib
- (2015) C. Campas et al. DRUGS OF THE FUTURE
- CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancerin Vitroandin Vivo
- (2012) Alessandro Antonelli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Synthesis and Structure–Activity Relationships of (Aryloxy)quinazoline Ureas as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors
- (2012) Antonio Garofalo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds
- (2012) Masanori Okaniwa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis
- (2011) M. Zillhardt et al. CLINICAL CANCER RESEARCH
- Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent
- (2011) Robert L. Hudkins et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
- (2010) Paul W. Manley et al. BIOORGANIC & MEDICINAL CHEMISTRY
- 8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors
- (2010) Robert L. Hudkins et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activityin Vitroandin Vivoin Papillary Dedifferentiated Thyroid Cancer
- (2010) Alessandro Antonelli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Analysis of Kinase Inhibitor Selectivity using a Thermodynamics-Based Partition Index
- (2010) Alan C. Cheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics
- (2009) Lindsay O. Kirkland et al. BIOCHEMICAL PHARMACOLOGY
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies
- (2009) Jack A. Bikker et al. JOURNAL OF MEDICINAL CHEMISTRY
- Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
- (2009) Fabio Zuccotto et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selectively Nonselective Kinase Inhibition: Striking the Right Balance
- (2009) Richard Morphy JOURNAL OF MEDICINAL CHEMISTRY
- Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes
- (2008) Richard M. Angell et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: Synthesis, SAR, and pharmacokinetic properties
- (2008) Deborah Choquette et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors
- (2008) David Bauer et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
- (2008) S. Giordano et al. CURRENT MEDICINAL CHEMISTRY
- Is there a case for selectively promiscuous anticancer drugs?
- (2008) Ariel Fernández et al. DRUG DISCOVERY TODAY
- Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition
- (2008) AC Backes et al. Expert Opinion on Drug Discovery
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- 7-Aminopyrazolo[1,5-a]pyrimidines as Potent Multitargeted Receptor Tyrosine Kinase Inhibitors
- (2008) Robin R. Frey et al. JOURNAL OF MEDICINAL CHEMISTRY
- 3-Amino-benzo[d]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases
- (2008) Zhiqin Ji et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evaluation of a Series of Naphthamides as Potent, Orally Active Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitors¶
- (2008) Matthew M. Weiss et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Guided Design of Aminopyrimidine Amides as Potent, Selective Inhibitors of Lymphocyte Specific Kinase: Synthesis, Structure–Activity Relationships, and Inhibition of in Vivo T Cell Activation
- (2008) Erin F. DiMauro et al. JOURNAL OF MEDICINAL CHEMISTRY
- Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation¶
- (2008) Jean-Christophe Harmange et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More